Kuste Biopharma initiates its first clinical trial

Kuste is excited to initiate the first clinical trial with our proprietary anti-inflaammatory drug Brimapitide (KU002), exploring the safety and efficacy in patients who suffer from Bladder Pain Syndrome/Interstitial Cystitis (BPS/IC). 

 

The study has gained approval from the Health Authority and Ethics Committees in The Netherlands, where patient recruitment is currently ongoing and will take place in up to three sites.

 The study is planned to be conducted also in other sites in Europe: Belgium and Sweden, following the approval from the respective Health Authority and Ethics Committee.

 For more information about Interstitial cystitis:

Kuste Biopharma

2 bis rue Tête d’Or
69006 Lyon

5 rue de Castiglione
75001 Paris

+33 (0) 481 133 530
contact@kustebiopharma.com

http://Logo-kuste-Biopharma-Vertical-desktop
Retour haut de page